retatrutide triple agonist gip glp-1 glucagon phase 2 obesity Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide
Pay in 4 interest-free payments of $6.12 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11




00967-0/asset/e600c3fc-c7b2-4bc5-adb8-0138decc3ad3/main.assets/gr3_lrg.jpg)






















